NVAX

Novavax, Inc.

14.39 USD
-0.01 (-0.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Novavax, Inc. stock is down -0.07% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48.28% of the previous 28 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
14 Jun 14:10 18 Oct, 2024 10.00 CALL 64 387
14 Jun 14:10 17 Jan, 2025 10.00 CALL 101 9554
14 Jun 14:11 17 Jan, 2025 10.00 CALL 63 9554
14 Jun 14:12 16 Jan, 2026 15.00 CALL 99 1503
14 Jun 14:16 17 Jan, 2025 5.00 CALL 240 13657
14 Jun 16:09 16 Jan, 2026 25.00 CALL 84 1596
14 Jun 16:11 21 Jun, 2024 14.00 CALL 446 70
14 Jun 16:28 16 Jan, 2026 10.00 PUT 360 13327
14 Jun 18:56 17 Jan, 2025 30.00 PUT 40 230
14 Jun 19:26 17 Jan, 2025 20.00 CALL 150 4483

About Novavax, Inc.

Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.